ASX:TLXBiotechs
Why Telix Pharmaceuticals Stock Is Up 8.6% And What's Next After FDA Glioma Imaging Approval
Telix Pharmaceuticals reported that the FDA has approved Pixclara, a fluorine 18 based FET PET imaging drug to help differentiate recurrent or progressive glioma from treatment related changes in both adults and children in the United States.
The approval of Pixclara as the only FDA cleared radiopharmaceutical imaging drug for glioma in the U.S. gives Telix Pharmaceuticals a differentiated diagnostic product that can plug directly into its existing Precision Medicine commercial and...

